Vericel to Report Second-Quarter 2025 Financial Results on July 31, 2025
Vericel Corporation (NASDAQ:VCEL), a leading provider of advanced therapies for sports medicine and severe burn care, has scheduled its second-quarter 2025 financial results announcement for July 31, 2025.
The company will host a conference call and webcast at 8:30 a.m. ET to discuss financial results and business highlights. Investors can access the live webcast through Vericel's Investor Relations website, with presentation slides available during the call. A replay will be accessible until July 31, 2026.
Vericel Corporation (NASDAQ:VCEL), leader nelle terapie avanzate per la medicina sportiva e il trattamento delle ustioni gravi, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 31 luglio 2025.
La società terrà una conference call e una webcast alle 8:30 a.m. ET per discutere i risultati finanziari e i principali sviluppi aziendali. Gli investitori potranno seguire la diretta streaming tramite il sito web delle Relazioni con gli Investitori di Vericel, con le slide della presentazione disponibili durante la chiamata. La registrazione sarà accessibile fino al 31 luglio 2026.
Vericel Corporation (NASDAQ:VCEL), un proveedor líder de terapias avanzadas para medicina deportiva y cuidado de quemaduras graves, ha programado el anuncio de resultados financieros del segundo trimestre de 2025 para el 31 de julio de 2025.
La compañía realizará una llamada conferencia y una transmisión en vivo a las 8:30 a.m. ET para discutir los resultados financieros y los aspectos destacados del negocio. Los inversores podrán acceder a la transmisión en vivo a través del sitio web de Relaciones con Inversores de Vericel, con las diapositivas de la presentación disponibles durante la llamada. La repetición estará disponible hasta el 31 de julio de 2026.
Vericel Corporation (NASDAQ:VCEL)은 스포츠 의학 및 중증 화상 치료를 위한 첨단 치료제의 선도 제공업체로서, 2025년 2분기 재무 실적 발표를 2025년 7월 31일로 예정하고 있습니다.
회사는 오전 8시 30분(동부시간)에 재무 실적 및 사업 하이라이트를 논의하는 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다. 투자자들은 Vericel 투자자 관계 웹사이트를 통해 라이브 웹캐스트에 접속할 수 있으며, 발표 자료는 통화 중에 제공됩니다. 녹화된 방송은 2026년 7월 31일까지 시청 가능합니다.
Vericel Corporation (NASDAQ:VCEL), un leader dans les thérapies avancées pour la médecine sportive et le traitement des brûlures graves, a programmé l'annonce des résultats financiers du deuxième trimestre 2025 pour le 31 juillet 2025.
La société organisera une conférence téléphonique et un webcast à 8h30 ET pour discuter des résultats financiers et des faits marquants de l'entreprise. Les investisseurs pourront accéder au webcast en direct via le site des Relations Investisseurs de Vericel, avec les diapositives de présentation disponibles pendant l'appel. Le replay sera accessible jusqu'au 31 juillet 2026.
Vericel Corporation (NASDAQ:VCEL), ein führender Anbieter fortschrittlicher Therapien für Sportmedizin und die Behandlung schwerer Verbrennungen, hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 am 31. Juli 2025 angekündigt.
Das Unternehmen wird eine Telefonkonferenz und einen Webcast um 8:30 Uhr ET abhalten, um die Finanzergebnisse und Geschäftshighlights zu besprechen. Investoren können den Live-Webcast über die Investor-Relations-Website von Vericel verfolgen; Präsentationsfolien sind während des Anrufs verfügbar. Eine Aufzeichnung wird bis zum 31. Juli 2026 zugänglich sein.
- None.
- None.
CAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its second-quarter 2025 financial results on Thursday, July 31, 2025. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.
The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Presentation slides for the conference call will be available on the webcast and on the website. A replay of the webcast will be available until July 31, 2026.
To participate by telephone, dial 855-303-0072 or +1 773-305-6837 if connecting from outside the U.S. When connected, please use passcode: 276790.
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
FAQ
When will Vericel (NASDAQ:VCEL) report Q2 2025 earnings?
How can investors access Vericel's Q2 2025 earnings call?
What is Vericel's main business focus?
How long will Vericel's Q2 2025 earnings call replay be available?
